Everest Medicines Acquires Exclusive VIS-101 License for Greater China, Southeast Asia

Everest Medicines has secured an exclusive license from Visara, a subsidiary of NovaBridge Biosciences, to develop, manufacture, and commercialize VIS-101 across Greater China, Singapore, South Korea, and certain Southeast Asian countries. VIS-101 is a novel bifunctional biologic targeting VEGF-A and ANG-2, designed to treat serious eye disorders such as wet age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO), and is anticipated to be Phase 3-ready in 2026. Everest Medicines will pay an upfront fee, reimburse prior expenses, and could pay up to $89 million in milestones plus royalties on net sales. This move marks Everest's entry into ophthalmology, a high-potential therapeutic area with significant unmet medical needs, especially in Asia where millions suffer from these eye conditions but only a fraction receive treatment. NovaBridge additionally appointed Ian Woo, President and CFO of Everest Medicines, to its Board of Directors, enhancing strategic collaboration. The global anti-VEGF ophthalmic drug market is projected to grow substantially, highlighting the commercial potential of VIS-101 in the region.